A new device has received food and drug administration approval for pancreatic cancer, offering a new tool in cancer treatment.

This wearable technology works by disrupting cancer cells, potentially slowing growth. While not a cure, this development in medical research provides a valuable addition to oncology strategies, buying time for patients.

🎯 What You’ll Learn in This Episode
• What Tumor Treating Fields actually are
• How the Optune device works
• Why pancreatic cancer is difficult to treat
• Why slowing tumor division may buy valuable treatment time
• The limitations of IV chemotherapy delivery to pancreatic tumors
• Why immune activation is critical for long-term response
• How multi-omics testing identifies personalized targets
• Why new technologies should be combined with precision strategies

📍 Envita Medical Centers – Scottsdale, AZ
🌐 Learn more: www.envita.com
📞 Speak with a care coordinator: 866-830-4576

“New technology can slow cancer — but long-term control often depends on activating the immune system.”

Disclaimer
This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.
________________________________________
Outcomes Disclaimer
The results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.

You can read the full peer-reviewed study at:

https://www.scirp.org/journal/paperinformation?paperid=132493